Business context and reporting period
RedHill Biopharma Ltd. filed this Form 20-F annual report for the fiscal year ended December 31, 2021. It is an annual filing, not a standalone fourth-quarter report; the filing text does not provide clear isolated Q4 financial results. The company is an Israel-based specialty biopharmaceutical business focused on gastrointestinal and infectious diseases. It markets Movantik, Talicia and Aemcolo in the U.S. and also advances clinical-stage candidates. Financial statements are prepared under IFRS as issued by the IASB, in U.S. dollars.
Key financial results and liquidity
| Metric (US$ millions, except per-share data) | 2021 | 2020 |
|---|---|---|
| Net revenue | 85.8 | 64.4 |
| Gross profit | 36.4 | 27.5 |
| Gross margin | 42.4% | 42.7% |
| Research and development expense | 29.5 | 16.5 |
| Selling and marketing expense | 55.6 | 49.3 |
| General and administrative expense | 32.4 | 25.4 |
| Operating loss | (81.1) | (63.7) |
| Net and comprehensive loss | (97.7) | (76.2) |
| Basic and diluted loss per ordinary share | $0.21 | $0.21 |
| Net cash used in operating activities | (65.0) | (48.6) |
Movantik generated $76.8 million of 2021 revenue; other products contributed $9.0 million. Three U.S. wholesale customers each represented approximately 31%–32% of revenue, creating substantial customer concentration. Cash and cash equivalents were $29.5 million, bank deposits $8.5 million and restricted cash $16.2 million at year-end. Thus, reported cash, deposits and restricted cash totaled approximately $54.2 million, but the restricted amount was not freely available for general use.
Year-end total liabilities were $172.3 million, including $83.6 million of carrying-value borrowings and $20.5 million payable for intangible-asset purchases. Total equity was $8.9 million. Net cash from financing activities was $73.5 million, primarily reflecting equity offerings and a strategic investment; investing activities used $8.1 million. The term loan bears interest at three-month LIBOR plus 6.7% from April 2021, subject to a 1.75% LIBOR floor, and includes a 4% revenue-interest payment on worldwide net revenue, subject to an annual cap.
Material changes versus the prior comparable period
- Revenue rose $21.4 million, or about 33%, mainly as Movantik and Talicia sales increased.
- Gross profit increased $8.9 million, while gross margin edged down to 42.4% from 42.7%.
- Operating loss widened by $17.5 million and net loss by $21.6 million. Higher commercial spending and R&D costs, including advancement of opaganib and RHB-107 COVID-19 programs, were major factors.
- Operating cash use increased by $16.5 million. The company raised $78.5 million net from share issuance in 2021, compared with $23.9 million in 2020, alongside option exercises and Kukbo’s first investment tranche.
- RedHill recorded an $8.9 million impairment of the Aemcolo intangible asset, concluding that it was entirely impaired amid depressed travel demand and the possibility of early license termination.
- After settling Movantik-related patent litigation, RedHill extended the estimated useful life of the acquired rights to 12.5 years from acquisition, affecting amortization estimates.
Outlook, commentary and principal risks
Management expects continued losses and negative operating cash flows while it funds commercialization and clinical development. It stated that existing capital resources should fund current and planned operations for at least 12 months, but also disclosed that resources are insufficient to complete development of all candidates and fully support operations until sustainable positive cash flow. The auditor identified liquidity and capital-resource forecasts as a critical audit matter, as well as the estimation of rebates. No specific revenue, profit or cash-flow guidance is provided.
- Financing and debt: Additional capital may be needed and could dilute shareholders. The HCRM facility is secured by substantially all RedHill U.S. assets, Talicia-related assets and RedHill U.S. equity. Covenants include a $16 million minimum cash balance, sales requirements and a minimum sales-force level; the company reported compliance at year-end. The filing describes the start of the sales covenant inconsistently in different sections, so the applicable timing should be verified.
- Commercial execution: Movantik is the main revenue source. Sales depend on reimbursement, market access, partners and manufacturers. Aemcolo demand has been materially affected by reduced travel; its U.S. license may be terminated by either party on advance notice. Talicia and Movantik also face branded and generic competition.
- Clinical and regulatory uncertainty: Opaganib’s global Phase 2/3 COVID-19 study did not meet its primary endpoint. Favorable findings described for patient subsets were post-hoc or prespecified subgroup analyses and do not establish approval or efficacy. RHB-204 Phase 3 enrollment was slow. Aemcolo pediatric postmarketing studies had pending FDA deadline-extension requests, and Movantik’s postmarketing cardiovascular safety study remained in progress.
- Other significant exposures: RedHill relies on third parties for manufacturing, supply and clinical trials; faces patent litigation concerning Movantik (Aether); and operates amid COVID-19-related commercial, trial and supply-chain disruption. The filing also identifies potential regulatory, product-liability, intellectual-property, cybersecurity, foreign-exchange and Israel-related political and security risks.
For post-year-end context, the filing reports a March 2022 exclusive South Korea license for opaganib, with a $1.5 million upfront payment and potential milestones and royalties. It also reports positive Phase 2 Part A results for RHB-107 in non-hospitalized COVID-19 patients; the study was not powered for efficacy, and further regulatory discussion was anticipated. These are subsequent developments, not 2021 results.
Important facts for investors to verify
- Review the complete audited IFRS statements and notes, including the cash-flow forecast assumptions behind management’s 12-month liquidity conclusion and the auditor’s liquidity critical audit matter.
- Confirm unrestricted liquidity, forthcoming Movantik and Daiichi Sankyo payments, debt service, the $16 million restricted-cash requirement and the precise sales-covenant measurement period.
- Assess the quality and sustainability of revenue: Movantik’s contribution, rebate accruals ($30.7 million at year-end), three-customer concentration and commercial product margins.
- Check developments in the Aether patent case, Movantik supply transition, Aemcolo license status and required postmarketing studies.
- Distinguish primary trial outcomes from subgroup analyses, and monitor regulatory feedback, confirmatory-study requirements and funding needs for the pipeline.